SPIRIT: Assessing Clinical Parameters Associated with Using IDegLira in Patients with Type 2 Diabetes in a Real-World Setting in Colombia-Reference-Cited by-同舟云学术

SPIRIT: Assessing Clinical Parameters Associated with Using IDegLira in Patients with Type 2 Diabetes in a Real-World Setting in Colombia

Published:2024-05-08 Issue:7 Volume:15 Page:1535-1545
ISSN:1869-6953
Container-title:Diabetes Therapy
language:en
Short-container-title:Diabetes Ther

Author:

Ramírez-Rincón Alex^ORCID,Henao-Carrillo Diana^ORCID,Omeara Miguel^ORCID,Oliveros Julio,Assaf José,Ordóñez Jaime E.^ORCID,Prasad Preethy,Alzate María Alejandra^ORCID

Funder

Novo Nordisk Colombia

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s13300-024-01593-8.pdf

Reference24 articles.

1. Liakos A, Karagiannis T, Avgerinos I, Malandris K, Tsapas A, Bekiari E. Management of type 2 diabetes in the new era. Hormones (Athens). 2023;22(4):677–84.

2. Buse JB, Vilsbøll T, Thurman J, et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care. 2014;37(11):2926–33.

3. American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S158–78.

4. Gough SCL, Bode B, Woo V, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2(11):885–93.

5. Linjawi S, Bode BW, Chaykin LB, et al. The efficacy of ideglira (insulin degludec/liraglutide combination) in adults with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist and oral therapy: DUAL III randomized clinical trial. Diabetes Ther. 2017;8(1):101–14.